P&G Health Q2 FY27: Standalone PAT Up 26% YoY to ₹111.5 Cr, Margins Expand, Tops Own Preview Range
PAT +25.94% YoY · revenue +17.72% · margins expanding
₹382.49 Cr
+17.72% YoY
₹111.51 Cr
+25.94% YoY
28.86%
+2pp YoY
₹67.18
Procter & Gamble Health's standalone PAT for Q2 FY27 (quarter ended September 30, 2026) came in at ₹111.51 Cr, up 25.9% YoY from ₹88.54 Cr and up 16.0% QoQ from ₹96.15 Cr. Revenue from operations rose 17.7% YoY to ₹382.49 Cr (from ₹324.92 Cr) and 5.2% QoQ (from ₹363.71 Cr). This quarter carries no exceptional item, unlike Q1 FY27 which had a ₹31.80 Cr one-off gain on the sale of the Worli office property — so the YoY comparison (also clean of one-offs on the Q2 FY26 side) is the cleanest read, and it shows a genuinely strong, non-one-off print rather than a base-effect illusion.
Q2 FY-2027 vs prior quarters
The margin story is operating leverage: total expenses grew only 12.1% YoY (₹210.85 Cr to ₹236.33 Cr) against 17.7% revenue growth, with cost of materials consumed actually flat-to-down and employee costs the main absolute increase. Net profit margin (PAT/total income) expanded to 28.9% from 26.8% a year ago and 26.2% last quarter — consistent expansion on both axes, pointing to price/mix holding up rather than the raw-material headwinds our pre-result preview had flagged as the key swing factor.
The stock went into the print at ₹5,954.5, up 7% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
EPS ₹67.18 (basic/diluted) vs ₹53.34 year-ago and ₹57.92 prior quarter (the latter boosted by Q1's exceptional gain; ₹38.77 pre-exceptional is the cleaner QoQ base)
Tax expense ₹38.54 Cr, effective rate ~25.7% on PBT of ₹150.05 Cr
Cash and cash equivalents nearly doubled to ₹322.86 Cr (from ₹177.24 Cr at FY26-end), aided by ₹33.64 Cr proceeds from the Worli property sale completed in Q1
Against our own pre-result preview — which pencilled in revenue of ₹350–365 Cr, an EBITDA margin watch of 26–27%, and normalized PAT growth of 8–12% off a soft Q1 (+7% revenue growth, margin pressure) — the actual print beats on every count: revenue above the range, and 25.9% YoY PAT growth roughly 2-3x the normalized growth the Street-thin preview had penciled in. The preview's watch items are resolved in the company's favour: revenue growth reaccelerated rather than stayed muted, and margins expanded rather than stayed under pressure. On the third watch item — full-year guidance — the company gives none on record, as before; management offers no formal outlook in this filing, consistent with its historical pattern of not guiding. A web search for hard analyst consensus specific to this print found none (PGHL has only sparse coverage, per the preview's own note of a single analyst rating), so vsStreet is marked unknown rather than inferred. No management press release/commentary beyond the regulatory filing was available to cross-check against print. The quarter's other corporate developments (trading window closure, AGM, director reappointment, dividend record date) are governance/calendar items unrelated to the operating print.
W1
Whether NPM (28.9% this quarter, up from 26.8% YoY) holds into H2 FY27 now that Q1's one-off property-sale gain has fully lapped
W2
Input-cost trend the pre-result preview flagged as the key headwind: cost of materials + traded goods grew well below revenue this quarter — watch if that gap holds next quarter
W3
Whether management finally issues formal FY27 guidance, a watch item our preview specifically flagged and which remains unresolved in this filing
Can PGHL Arrest Growth Slowdown Amid Raw Material Headwinds?
After Q1's 7% growth and margin pressure from spiking input costs, the Street watches whether PGHL's fundamentals stabilize or face further headwinds in Q2.
The Setup
Procter & Gamble Health reported Q1 FY27 (ended June 30, 2026) with revenue of ₹364 Cr, up 7.4% YoY—a sharp deceleration from the 19% growth in Q4 FY26 and the mid-teens run-rate of FY26. Reported profit after tax jumped 45% to ₹96 Cr, but ₹31.80 Cr was a one-time gain from the sale of its Worli office premises; normalized PAT rose only 9.5%. The margin story was mixed: EBITDA margin expanded 71 bps to 27.38%, but raw material costs surged 34.88% YoY, eating 450 bps of revenue. The company offered no guidance for the remainder of FY27 and did not disclose category-wise sales or volume trends. For Q2, the Street is watching whether PGHL can stabilize growth and whether margin pressure from spiking input costs will persist.
~₹350–365 Cr
Mid-single-digit growth (4–7% YoY); continued slowdown from prior-year trajectory.
~26–27%
Risk of compression if raw material costs remain elevated; Q1 benefited from modest 71-bp expansion despite 450-bp input-cost headwind.
~8–12%
If Q1's 9.5% normalized growth holds, expect similar low-double-digit expansion; cyclical cost cycle the key variable.
What a Strong vs Weak Print Looks Like
Strong: Revenue ₹365+ Cr with mid-single-digit growth, EBITDA margin at or above 27.5%, and evidence that raw material cost inflation is moderating (either in absolute terms or as a share of revenue). Any commentary on category performance or guidance for H2 FY27 would signal management confidence. Weak: Revenue below ₹350 Cr or growth below 5% YoY, EBITDA margin compressing below 26%, or evidence that raw material costs are still rising faster than pricing can absorb. No guidance and continued silence on category trends would suggest ongoing headwinds.
Is PGHL On Track?
No full-year or medium-term guidance was disclosed in Q1, so tracking against a pre-announced target is not possible. However, the deceleration from 19% (Q4 FY26) to 7.4% (Q1 FY27) is notable and suggests cyclical headwinds or competitive pressure. If Q2 shows similar 7–9% growth, PGHL would be tracking to single-digit revenue growth for H1 FY27—a significant slowdown from the 16% FY26 full-year baseline and the 19% Q4 momentum. The raw material cost spike is temporary cyclical pressure, but it has already eaten deep into margins, limiting upside unless pricing or mix improves.
What the Street Says
Since Last Quarter
Routine corporate actions: Trading window closed Oct 1, 2026 (48 hours after result announcement, standard). S. Madhavan re-appointed as Independent Director (Sep 3, 2026 AGM). SEBI special window for share-deed re-lodgement extended to Feb 4, 2027 (routine administrative).
No promoter or insider signals: Promoter stake stable at 51.82% across all filed quarters (FY27 Q1 through FY25 Q4). FII holdings ticked up 13 bp to 6.33%, while DII slipped 123 bp to 12.44%—modest flows, no material change. No pledges or off-market transactions reported.
What to Watch on Result Day
1 · Revenue growth trajectory
Does Q2 stabilize at ~7% or accelerate back toward double digits? A continuation of deceleration (below 5%) signals deeper competitive or demand issues. Management commentary on category performance (antihistamines, vitamins, decongestants) and volume trends will be critical.
2 · Margin resilience
With raw material costs having surged 35% YoY in Q1, watch whether the 27.38% EBITDA margin holds in Q2 or compresses. If pricing or cost-reduction efforts have offset input inflation, that's a green flag. If margin contracts below 26%, it signals pricing lag.
3 · Full-year guidance (finally?)
PGHL offered none in Q1. A FY27 revenue or PAT guidance—even a range—would anchor Street expectations and reduce uncertainty. Absent guidance, focus on management's read of H2 demand, raw material outlook, and pricing strategy.
PGHL's Q2 result arrives amid growth deceleration and raw material headwinds that have compressed margins despite a strong brand portfolio in OTC pharma. The stock's 30% pullback from ATH reflects the Street's caution on near-term execution. What matters on Nov 2: whether Q2 revenue stabilizes in mid-single digits (a relief after Q1's slowdown), whether EBITDA margin holds above 27% (or compresses below, signaling pricing lag), and whether management finally articulates a full-year outlook or H2 inflection signal. Thin analyst coverage and no forward guidance mean the result itself will set the narrative.